Compare Charles River Laboratories Intl. Inc (CRL) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Sunrun Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.51 (market cap $11.14B), while Sunrun Inc trades at $12.74 (market cap $3.05B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.7× Sunrun Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| CRL | RUN | |
|---|---|---|
Market Cap | $11.14B | $3.05B |
Sector | Health | Technology |
52-Week High | $233.60 | $21.41 |
52-Week Low | $145.57 | $9.07 |
Enterprise Value | $14.00B | $17.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Sunrun (RUN) trades at $12.41, down 0.48% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The company reported strong profitability with a 17.88% net income margin and ROE of 19.06%, while valuation metrics like P/E of 6 and P/B of 0.91 suggest potential undervaluation. Recent news highlights a major partnership with Tesla and Renew Home for a 16-gigawatt virtual power plant, driving investor interest in grid-support initiatives tied to AI data center demand.
The stock presents a mixed outlook: analyst consensus is strongly bullish with a $17.09 price target (62% buy ratings), but negative operating cash flow and high debt-to-asset ratio of 70.76% pose risks. Growth catalysts include expanding revenue and margin trends, though execution on new ventures and macroeconomic pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
